Salix Pharmaceuticals (NASDAQ:SLXP) is committing more than $1.1 million to the American Gastroenterological Association Research Foundation to support research into digestive diseases.
The funding, to be given over five years, will support grants for young investigators in gastroenterology and hepatology. The grants help provide researchers with the tools to discover ways to better diagnose, treat and cure digestive diseases.
Raleigh-based Salix specializes in developing drugs that address gastrointestinal (GI) disorders. The AGA Research Foundation is the foundation of the American Gastroenterological Association (AGA), a professional society representing gastroenterologists and hepatologists worldwide. The foundation’s mission is to raise funds to support young researchers in gastroenterology and hepatology. The AGA Research Foundation awards nearly $1.2 million in research grants each year.